Develops a patented, low‑cost, scalable method to extract Ra‑224 and Ac‑225 from thorium‑232 stockpiles for use in targeted alpha therapies. Provides stable isotope supply to pharmaceutical developers to enable R&D and commercialization of radioimmunotherapy (TAT) drugs.